Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Abstract

Elevated pretreatment NLR might be a potential biomarker of worse response to first-line platinum-based chemotherapy and shorter PFS and OS for advanced NSCLC patients. To confirm these findings, larger, prospective and randomized studies are needed.

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

“…32 Of interest, Yao et al found a prognostic role for pretreatment NLR in NSCLC patients treated with first-line platinum-based chemotherapy. 33 However, this result was not confirmed in our calibration group, probably because of the small sample of patients included.…”

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

“…The characteristics of the 18 studies are summarized in Table I. A total of 7 studies were conducted in Western countries, including the UK (17,26,34), USA (28), Spain (20) and Italy (22,34), 1 study was performed in Turkey (23), and 10 studies were performed in East Asian countries, including Japan (18,19,31,32), Korea (21,25) and China (24,27,30,33). The study published by Mitchell et al (29) included patient data from 33 countries.…”

“…The included studies evaluated 16 populations of patients with NSCLC (17-24,26-29,31-34) and 2 populations of patients with SCLC (25,30). The 2 studies on SCLC reported tumor staging information as limited and extensive disease, so only the staging information from the studies regarding NSCLC were considered Only 1 study by Sarraf et al (17) evaluated all tumor stages, 8 studies evaluated early-stage tumors (23,(26)(27)(28)(29)(31)(32)(33), and 6 studies evaluated late-stage tumors (18,(20)(21)(22)24,34). The study by Tomita et al (19) evaluated stages IA/III/IV.…”

“…A total of 7 studies with 8 cohorts (18,21,22,24,25,30,34) including 1,581 patients evaluated the association between elevated pretreatment NLR and PFS among patients with lung cancer. Significant heterogeneity was also detected among these studies (I 2 =76.2%, P heterogeneity <0.001).…”

Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis?

“…Furthermore, normalization of NLR after one cycle of chemotherapy resulted in improved progression-free survival (Chua et al, 2011). Yao et al (2013) have investigated the association between NLR and therapy response and survival in 182 advanced NSCLC patients receiving firstline platinum-based chemotherapy and found that high pretreatment NLR was associated with worse response to first-line platinum-based chemotherapy and shorter survival (Yao et al, 2013).…”